GlassScriptPhysician profile
Manju George
NPI 1912054446
$28,444.01
in general payments reported to CMS, 2019-2025
29 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $1,332 · 2021: $722 · 2022: $1,072 · 2023: $1,556 · 2024: $8,375 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $6,316 · Honoraria: $2,800 · Travel and Lodging: $1,031 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $857 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,450.29 |
| Food and Beverage | $6,316.25 |
| Honoraria | $2,800.00 |
| Travel and Lodging | $1,030.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $857.25 |
| Education | $106.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,192.70 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $4,763.79 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $3,520.30 | 2023-2024 | Vtama |
| Incyte Corporation | $3,408.55 | 2021-2025 | Opzelura, Opzelura |
| Abeona Therapeutics, INC. | $2,850.00 | 2025 | Zevaskyn |
| Almirall LLC | $1,483.93 | 2019-2025 | Seysara, Klisyri |
| Regeneron Healthcare Solutions, INC. | $1,420.47 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $1,351.05 | 2024-2025 | Adbry |
| Genzyme Corporation | $791.32 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $755.43 | 2021-2025 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $733.13 | 2020-2025 | Aklief, Nemluvio, Epsolay |
| Organon LLC | $410.81 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $343.73 | 2021-2024 | Jublia, Arazlo, Duobrii |
| Lnhc, INC | $315.61 | 2025 | Zelsuvmi |
| Sanofi-Aventis U.S. LLC | $191.72 | 2020-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165.69 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $143.60 | 2019-2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $129.16 | 2022-2025 | |
| Journey Medical Corporation | $122.76 | 2019-2023 | |
| Abbvie INC. | $91.64 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $70.09 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $53.86 | 2023-2024 | Ycanth |
| Dermira, INC. | $30.77 | 2019-2020 | |
| Ucb, INC. | $24.23 | 2025 | Bimzelx |
| Gilead Sciences, INC. | $20.24 | 2020 | |
| Medtronic, INC. | $19.36 | 2022 | |
| Strata Skin Sciences, INC. | $18.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.91 | 2024 | Spevigo |
| Pierre Fabre Pharmaceuticals, INC. | $4.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manju George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.